Immunotherapy improves one-year survival rate of esophageal cancer patients in China

From September 27 to October 1, one of the most famous and influential professional oncology academic conferences in the world, "2019 European Society of oncology and Internal Medicine annual meeting (ESMO)" was held in Barcelona, Spain During the meeting, the first "keynote-181 study" on immunotherapy for esophageal cancer in China was officially released Keynote-181 is a large-scale global multicenter clinical trial, which aims to explore whether immunotherapy with pabolizumab can prolong the overall survival of patients with locally advanced or metastatic esophageal squamous cell carcinoma who have previously received first-line systemic treatment The latest cancer report released by China National Cancer Center in 2019 showed that 246 thousand cases of new esophageal cancer in China were in 2015, 188 thousand cases died, incidence rate and mortality rate ranked sixth and fourth of all malignant tumors, accounting for about half of the world's total Operation is the first choice for the treatment of esophageal cancer, but 70% of esophageal cancer patients lost the chance of operation due to the late detection and high tumor load, and the five-year survival rate is only 15% - 20% This part of patients often recur after radiotherapy and chemotherapy, and then use combined chemotherapy after recurrences The survival period of patients is more than one year As one of the "Chinese characteristic" tumors, esophageal cancer has been faced with the problems of lack of treatment plan and poor prognosis for a long time Keynote-181 research shows that Chinese esophageal cancer patients have better response to immunotherapy and more benefits Pabolizumab increased the median overall survival time from 5.6 months to 8.4 months, reduced the risk of death or progression by 45%, reduced the one-year survival rate from 16.7% to 36.3%, and reduced the incidence of side effects by half Professor Shen Lin, who led the study in China and vice president of Cancer Hospital of Peking University, said that the data of keynote-181 study in Chinese population confirmed that the survival benefits of Chinese patients using pabolizumab immunotherapy were significantly better than that of global population The data of this study prove that immunotherapy should be a new standard of esophageal cancer treatment in China compared with the standard chemotherapy treatment of esophageal cancer in the past, so as to break the current situation of low effective rate, large side effects and unsatisfactory effect of clinical esophageal cancer treatment Immunotherapy will significantly prolong the survival of patients, reduce the annual mortality of esophageal cancer, improve the quality of life of patients, and improve the overall efficiency of esophageal cancer treatment in China It is understood that the national drug review center has listed pabolizumab in the priority review list, and is expected to be approved as a new indication of esophageal cancer early next year Recommended conference of editor in chief: 2019 Wuxi International Biomedical forum and the 9th International Conference on cell death & Disease - new drug research and development: http://meeting.bioon.com/bcdd? __token=liaodefeng